Komori
Taoka Chemical (4113) · InitiativeDropped

Measures to prevent the spread of COVID-19

First written in FY2020. 7 of 9 entries say "Restated". Latest entry: FY2024.

9entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020 – FY20242020: 320202021: 420212022: 120222023: 020232024: 12024
Same theme, other companies
Response to COVID-19 and Transformation of Work StylesA theme 730 companies write about · 209 as a headwind · 482 as a tailwind

The whole theme swung hardest in 2026: 2 of 7 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 734 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024DroppedAnnual report

    「As social and economic activity continued to normalise following the COVID-19 pandemic, the economy entered a gradual recovery trend.」

    There is no separate disclosure for the year explaining measures to prevent the spread of COVID-19.
  2. FY2022-Q3RestatedAnnual report

    「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the nine-month period of the third quarter of the current consolidated fiscal year.」

    The company has continued its infectious-disease control measures in the domestic business and maintained an operating rate at the same level as under normal conditions.
  3. FY2022-Q2RestatedAnnual report

    「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the six-month period of the second quarter of the current consolidated fiscal year.」

    The company has continued its infectious-disease control measures in the domestic business and maintained an operating rate at the same level as under normal conditions.
  4. FY2022-Q1RestatedAnnual report

    「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the three-month period of the first quarter of the current consolidated fiscal year.」

    The company has continued its infectious-disease control measures in the domestic business and maintained an operating rate at the same level as under normal conditions.
  5. FY2021RestatedAnnual report

    「The Company and its domestic subsidiaries have continued operating with stringent measures in place, and have maintained an operating rate at the same level as under normal conditions even after the end of the fiscal year.」

    The company has continued its policy and practice of maintaining an operating rate at the same level as under normal conditions while implementing infectious-disease control measures in the domestic business.
  6. FY2021-Q3RestatedAnnual report

    「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the nine-month period of the third quarter of the current consolidated fiscal year.」

    The company has continued its infectious-disease control measures in the domestic business and maintained an operating rate at the same level as under normal conditions.
  7. FY2021-Q2RestatedAnnual report

    「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the six-month period of the second quarter of the current consolidated fiscal year.」

    The company has continued its infectious-disease control measures in the domestic business and maintained an operating rate at the same level as under normal conditions.
  8. FY2021-Q1RestatedAnnual report

    「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the three-month period of the first quarter of the current consolidated fiscal year.」

    The domestic business has continued operating with infectious-disease control measures in place and has maintained an operating rate at the same level as under normal conditions since the end of the quarter.
  9. FY2020First statedAnnual report

    「We are taking company-wide measures to prevent the spread of COVID-19 and other infectious diseases, including health checks for all employees, encouraging handwashing and alcohol disinfection, requiring mask wearing, recommending staggered working hours and telework, and in principle prohibiting meetings and business travel.」

    The company newly disclosed company-wide measures against infectious diseases, including health checks, disinfection, masks, staggered working hours, telework, and restrictions on meetings and business travel.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Taoka Chemical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.